Summary
BCG administered intraperitoneally (IP) was shown to have an immunoprophylactic effect against an ascites tumour. The dosage used was shown to have no immunosuppressive effects, as measured by subcutaneous tumour growth and delayed type hypersensitivity (DTH). In C57BL mice BCG was found to enhance DTH, in contrast with previous immunogenetic studies. The relationship between previously reported BCG-induced immunosuppression and immunotherapy is discussed.
Similar content being viewed by others
References
Bailey, N. T. J. 1981. Statistical Methods in Biology. 2nd Edition. Hodder and Stoughton, London, up. 49.
Barker, C. F. and Billingham, R. E. 1977. Immunologically privileged sites. Adv. Immunol. 25, 1.
Boyle, W. 1968. An extension of the51Cr-release assay for the estimation of mouse cytotoxins. Transplantation 6, 761.
Brazil, J. 1976. M.Sc. thesis, National University of Ireland’, p. 64.
Chee, D. O. and Bodurtha, A. J. 1974. Facilitation and inhibition of B16 melanoma by BCGin vivo and by lymphoid cells from BCG treated micein vitro. Int. J. Cancer 14, 137.
Corsini, A. C., Bellucci, S. B. and Costa, M. G. 1979. A simple method of evaluating delayed type hypersensitivity in mice. J. Immunol. Methods 30, 195.
Currie, G. A. and Bagshawe, K. D. 1968. The role of sialic acid in antigen expression: further studies of the Landschutz ascites tumour. Br. J. Cancer 22, 843.
Florentin, I., Huchet, R., Bruly-Rosset, M., Halle-Dannenko, O. and Mathe, G. 1976. Studies on the mechanisms of action of BCG. Cancer Immunol. Immunother. 1, 31.
Gray, J. D., Brooks, C. G. and Baldwin, R. W. 1981. Detection of eithfr rapidly cytolytic macrophages of NK cells in ‘activated’ peritoneal exudate depends in the method of analysis and the target cell type. Immunology 42, 561.
Kaledin, V. I., Kurunov, Y. N., Matienko, N.A., Nikolin, V. P. 1978. Stimulation of tumour growth in mice by high doses of BCG. J. Natl. Cancer Inst. 61, 1393.
Kato, K., Yamamoto, K., Kakinuma, M., Ishihara, C. and Azuma, I. 1981. Suppression of BCG cell wall induced delayed-type hypersensitivity by pre-treatment. I. Induction of adherent suppressor cell by live BCG injection and their characterization. Immunology 42, 259.
Klimpel, G.R. and Henney, C. S. 1978. BCG induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T cell generationin vitro. J. Immunol. 120, 563.
Miller, T. E., Mackaness, G. B. and Lagrange, P. H. 1973. Immunopotentiation with BCG, II. Modulation of the response to sheep red blood cells. J. Natl. Cancer Inst. 51, 1669.
Morton, D. L., Eilber, F. R., Malmgren, R. A. and Wood, W. C. 1970. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158.
Nelson, D. S., Nelson, M. and Hopper, K. E. 1980. Mechanism of resistance of mice to syngeneic methylcholanthrene induced fibrosarcomas. Adv. Exp. Med. Biol. 12113, 541.
PPeto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, DD R., Howard, S. V., Mantel, N., McPherson, K., Peto, J. and Smith, P. G. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient (II Analysis and Examples). Br. J. Cancer 35, 1.
Prehn, R. T. and Main, J. M. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18, 769.
Prehn, R. T. 1972. The immune reaction as a stimulator of tumour growth. Science 176, 170.
Ruckdeschel, J. C., McKneally, M. F., Baxter, D. H., De Vore, C., Kellar, S., Killam, D., Caradonna, R., Sedransk, N., Mcllduff, J. B. and Horton, J. 1981. Regional immunotherapy has a detrimental effect on the response to combined irradiation and chemotherapy in locally advanced; non-small cell bronchogenic carcinoma. Cancer Immunol. Immunother. 11, 277.
Schrier, D. J. Sternick, J. L., Allen, E. M. and Moore, V. L. 1981. Genetic basis of BCG-induced suppression of delayed hypersensitivity. Nature 289, 405.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roche, W.R., McLaughlin, H. The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. I.J.M.S. 152, 303–306 (1983). https://doi.org/10.1007/BF02945302
Issue Date:
DOI: https://doi.org/10.1007/BF02945302